Market Overview

Teva's Litigation Risks Weigh Against Stabilizing Fundamentals, Analyst Says

Share:
Teva's Litigation Risks Weigh Against Stabilizing Fundamentals, Analyst Says

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported strong quarterly results, prompting an analyst at Barclays to upgrade the stock.

The Teva Analyst: Balaji Prasad upgraded Teva from Underweight to Equal-Weight and increased the price target from $10 to $13.

The Teva Thesis: Teva reported in-line second-quarter results and reiterated its fiscal year revenue and EPS guidance.

Among other things, Ajovy auto-injector saw an improvement in prescription trends and the company has laid long-term growth foundation with the Alvotech biosimilar partnership for five U.S. biosimilar candidates, which represented about $35 billion in innovator sales, the analyst noted.

Among Prasad's key takeaways are:

  • Positive prospects for Ajovy in both the U.S. and outside of the U.S.
  • Austedo sales on track to meet fiscal year 2020 target
  • Copaxone sales beating expectations
  • Stable free cash flow
  • Execution on long-term targets

See Also: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

Teva's 2023 financial goals of more than 80% cash conversion and 28% EBIT margins are achievable and sustainable, according to the analyst.

"While we are cautious on potential legal risks arising from Opioid litigations and Gx Price Fixing cases, we acknowledge the stabilizing fundamentals, improving FCF Generation and reduced leverage profile," Prasat said in the note.

TEVA Price Action: Teva shares were sliding 3.6% to $12.20, surrendering some of their 7.3% earnings-induced gains made Wednesday.

Latest Ratings for TEVA

DateFirmActionFromTo
Aug 2020BarclaysUpgradesUnderweightEqual-Weight
Aug 2020SVB LeerinkMaintainsMarket Perform
Jul 2020Goldman SachsInitiates Coverage OnNeutral

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Balaji Prasad BarclaysAnalyst Color Earnings Upgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
BIIBRBC CapitalMaintains277.0
RLICompass PointInitiates Coverage On90.0
CSCOWolfe ResearchDowngrades42.0
NKEBarclaysMaintains132.0
GILDRBC CapitalMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com